Review article · 2015 · Open access

Advances in Alzheimer’s Disease Drug Development

Michael S. Rafii, Paul S. S. Aisen

BMC Medicine, 13(1), 62 · Published 25 March 2015 · DOI 10.1186/s12916-015-0297-4

Free PDFView at the publisherCite this paper

In brief

“Advances in Alzheimer’s Disease Drug Development” is a 2015 review article by Michael S. Rafii and Paul S. S. Aisen, published in BMC Medicine. OpenAlex counts 98 citations as of 15 November 2026. It is open access under a CC BY licence: the full text is free to read at BMC Medicine.

Citations
98
Most cited in
2016 (28)
Field-weighted impact
2.01
References
46
Authors
2

Abstract

Alzheimer's disease (AD) is the foremost cause of dementia worldwide. Clinically, AD manifests as progressive memory impairment followed by a gradual decline in other cognitive abilities leading to complete functional dependency. Recent biomarker studies indicate that AD is characterized by a long asymptomatic phase, with the development of pathology occurring at least a decade prior to the onset of any symptoms. Current FDA-approved treatments target neurotransmitter abnormalities associated with the disease but do not affect what is believed to be the underlying etiology. In this review, we briefly discuss the most recent therapeutic strategies being employed in AD clinical trials, as well the scientific rationale with which they have been developed.

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Rafii, M. S., & Aisen, P. S. S. (2015). Advances in Alzheimer’s Disease Drug Development. BMC Medicine, 13(1), 62. https://doi.org/10.1186/s12916-015-0297-4

MLA 9

Rafii, Michael S., and Paul S. S. Aisen. “Advances in Alzheimer’s Disease Drug Development.” BMC Medicine, vol. 13, no. 1, 2015, p. 62. https://doi.org/10.1186/s12916-015-0297-4.

Chicago

Rafii, Michael S. and Paul S. S. Aisen. 2015. “Advances in Alzheimer’s Disease Drug Development.” BMC Medicine 13 (1): 62. https://doi.org/10.1186/s12916-015-0297-4.

Harvard

Rafii, M. S. and Aisen, P. S. S. (2015) ‘Advances in Alzheimer’s Disease Drug Development’, BMC Medicine, 13(1), p. 62. doi:10.1186/s12916-015-0297-4.

IEEE

M. S. Rafii and P. S. S. Aisen, “Advances in Alzheimer’s Disease Drug Development,” BMC Medicine, vol. 13, no. 1, p. 62, 2015, doi: 10.1186/s12916-015-0297-4.

BibTeX

@article{rafii2015advances,
  title     = {{Advances in Alzheimer’s Disease Drug Development}},
  author    = {Rafii, Michael S. and Aisen, Paul S. S.},
  journal   = {BMC Medicine},
  year      = {2015},
  volume    = {13},
  number    = {1},
  pages     = {62},
  doi       = {10.1186/s12916-015-0297-4},
  url       = {https://doi.org/10.1186/s12916-015-0297-4}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Citations by year

YearCitationsShare of the best year
20162828
201799
20181616
201966
20201212
202166
202266
202366
202433
202511

Its field-weighted citation impact is 2.01: it has been cited 2.01 times as often as the average work of the same field, type and year (1.00 is the world average).

Topic and keywords

Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments

  • Alzheimer's disease
  • drug development
  • dementia
  • memory impairment
  • biomarkers
  • asymptomatic phase
  • neurotransmitter abnormalities
  • clinical trials

Work with this paper

Most-cited papers in Neuroscience

All highly cited Neuroscience papers

Questions about this paper

How do I cite this paper in APA style?

Rafii, M. S., & Aisen, P. S. S. (2015). Advances in Alzheimer’s Disease Drug Development. BMC Medicine, 13(1), 62. https://doi.org/10.1186/s12916-015-0297-4

How many times has this paper been cited?

98 times, according to OpenAlex on 15 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

Yes. It is open access: read the free full text at BMC Medicine.

Who wrote this paper?

Michael S. Rafii, Paul S. S. Aisen.

What is the DOI of this paper?

10.1186/s12916-015-0297-4. The permanent link is https://doi.org/10.1186/s12916-015-0297-4.

Bibliographic data from OpenAlex (CC0), last checked 15 November 2026. ResearchGuru does not host this paper; the links go to the publisher or the repository that does.